Pharmacokinetics of Didanosine in Antepartum and Postpartum Human Immunodeficiency Virus-Infected Pregnant Women and Their Neonates: An AIDS Clinical Trials Group Study

Didanosine (ddI) pharmacokinetics in antepartum and postpartum human immunodeficiency virus (HIV)‐infected women and their neonates were studied. HIV-infected pregnant women received an intravenous (iv) ddI infusion (1.6 mg/kg/h) or an oral dose (200 mg bid or 125 mg bid) at 31 weeks antepartum and 6 weeks postpartum. Blood samples were obtained regularly up to 6 or 8 h after drug administration. The same oral dose of ddI (bid) was administered until labor began. Then, ddI was infused iv until delivery. An oral pharmacokinetic study (60 mg/m 2 ) was conducted in infants at day 1 and at week 6 after birth. Plasma concentrations of ddI were measured by radioimmunoassay. After iv ddI administration, only the maternal plasma clearance was found to be significantly increased antepartum (1028 5 mL/min) versus postpartum ( mL/min). No pharmacokinetic parameters after 231 707 5 213 oral administration were significantly affected by pregnancy. The pharmacokinetics of ddI in the neonates were highly variable. We conclude that the oral ddI dose need not be adjusted during pregnancy.